Maraviroc: A Review of its Use in the Management of CCR5-Tropic HIV-1 Infection

Maraviroc (Celsentri®; Selzentry®) is a CCR5 coreceptor antagonist used in the treatment of CCR5-tropic HIV-1 infection. Administered orally twice daily, maraviroc, in combination with optimized background therapy regimens, showed good virological and immunological efficacy over 48 weeks in antiretr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2010-06, Vol.70 (9), p.1189-1213
1. Verfasser:	Perry, Caroline M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adis Drug Evaluation Adolescent Adult Antiretroviral Therapy, Highly Active CCR5 Receptor Antagonists Cyclohexanes - adverse effects Cyclohexanes - economics Cyclohexanes - pharmacokinetics Cyclohexanes - therapeutic use Dosage and administration Drug therapy Drug therapy, Combination Female Health aspects HIV Fusion Inhibitors - adverse effects HIV Fusion Inhibitors - economics HIV Fusion Inhibitors - pharmacokinetics HIV Fusion Inhibitors - therapeutic use HIV infection HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - virology HIV-1 - drug effects HIV-1 - physiology Humans Internal Medicine Male Maraviroc Medicine Medicine & Public Health Patient outcomes Pharmacology/Toxicology Pharmacotherapy Randomized Controlled Trials as Topic Receptors, CCR5 - metabolism Treatment Failure Treatment Outcome Triazoles - adverse effects Triazoles - economics Triazoles - pharmacokinetics Triazoles - therapeutic use Viral Load Viral Tropism Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!